gdc

Lymphoma

Yescarta Leads to Long-Term Responses in  Patients with Advanced Follicular Lymphoma or Marginal-Zone Lymphoma
Lymphoma
A total of 80% of patients with relapsed (coming back) or refractory (not responding to therapy) slow-growing (indolent) non-Hodgkin lymphoma (NHL)—including patients with follicular lymphoma or marginal-zone lymphoma (MZL)—achieved a complete response (no sign of cancer) to Yescarta (axicabtagene ciloleucel), an anti-CD19 CAR T-cell therapy.
Keytruda New Standard of Care for Relapsed or Refractory Classical Hodgkin Lymphoma
Lymphoma
Treatment with the PD-1 inhibitor Keytruda (permbrolizumab) significantly extended progression-free survival (PFS) in patients with classical Hodgkin lymphoma compared with standard treatment with Adcetris (brentuximab vedotin), according to the results of the phase 3 KEYNOTE-204 clinical trial reported at the ASCO 2020 virtual annual meeting.
Keytruda Immunotherapy Prolongs Survival in Patients with Relapsed or Refractory Hodgkin Lymphoma
Lymphoma
Using the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, prolongs the time without disease progression in patients with relapsed (coming back) or refractory (not responding to treatment) classical Hodgkin lymphoma compared with the current standard of therapy of Adcetris (brentuximab vedotin), an antibody–drug conjugate.
CONQUER Cam: A Spotlight on Brad Power
CONQUER CamLymphomaPatient Stories
Bradford Power took the credibility he had as a patient diagnosed with cancer and used it to fuel his purpose and mission of helping others navigate their cancer diagnosis and treatment.
7-Year-Old Lynden Raises Money for Cancer Research While Fighting Lymphoma
LymphomaPediatric Cancer
A year before Lynden was diagnosed with cancer, she cut off her hair and donated it to help kids with cancer. After her diagnosis, she launched a new project. She is just getting started, but so far she has raised more than $65,000 for pediatric cancer research.
Drugs for Lymphoma
Lymphoma
Here are the drugs and financial support services available to patients receiving treatment for Lymphoma.
Brukinsa FDA Approved for Mantle-Cell Lymphoma
Lymphoma
In November 2019, the FDA approved the second Bruton tyrosine kinase inhibitor for the treatment of adults with mantle-cell lymphoma (a type of non-Hodgkin lymphoma) who have received at least 1 previous therapy.
Working with Your Treatment Team to Decide on the Best Options for You
LeukemiaLymphomaMultiple Myeloma
People who are diagnosed with blood cancer need to learn enough about it without being overwhelmed, and to take part in their treatment decisions. Communicate important personal information to your care team.
Polivy a New Targeted Immunotherapy Approved for Patients with B-Cell Lymphoma
FDA Approvals, News & UpdatesLymphomaNewsworthy
In June 2019, the FDA approved a new type of immunotherapy called Polivy, for use in combination with other drugs, in patients with previously treated diffuse large B-cell lymphoma (DLBCL), offering new options for patients whose cancer has returned.
Page 1 of 5
Results 1 - 10 of 42

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country